Oncology

Gilead’s Trodelvy approved in metastatic urothelial cancer

  • by

Gilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer.  Trodelvy (sacituzumab govitecan) has been approved for locally advanced or metastatic urothelial cancer, following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor immunotherapy. The US pharma hopes that the… Read More »Gilead’s Trodelvy approved in metastatic urothelial cancer

Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching

  • by

What You Should Know: – Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, VIPER, into community-based oncology practices throughout the Cardinal network. VIPER will be a part of Cardinal Health’s new Navista advanced… Read More »Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching

3rd Cell Engager Summit

  • by

With that in mind, the 3rd Cell Engager Summit (June 30 – July 1) is the only industry-led meeting focused on developing multi-specific cell engaging therapies in solid tumor indications, and accelerating early discovery innovation into the clinic. With over 32 world-class speakers set to share their ground-breaking insights, this… Read More »3rd Cell Engager Summit

Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline

  • by

Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel Exelixis get an exclusive license to the panel of mAb against an undisclosed oncology target for biologics… Read More »Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline

2nd TCR-based Therapies Summit

  • by

The 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity, density and binding affinity for solid tumor indications. Join this exclusive community online to virtually network and learn from the leading experts in pharma, biotech and… Read More »2nd TCR-based Therapies Summit

Startup banks on immune-system memory to tackle cancer

  • by

Loki Therapeutics is advancing research that leverages the immune system’s ability to recall childhood vaccinations and direct it against cancer. The company’s lead therapy candidate could enter phase 1 clinical trials this year.

Frenova Begins Patient Enrollment to Build World’s Largest Genomics Registry for Kidney Disease

  • by

What You Should Know: – Frenova Renal Research, a global division of Fresenius Medical Care, announced today that it has started to enroll patients in its new endeavor to build the world’s largest genomics registry targeting kidney disease. – The registry will be used to help… Read More »Frenova Begins Patient Enrollment to Build World’s Largest Genomics Registry for Kidney Disease

Myovant Signs Agreement with Pfizer to Develop and Commercialize Relugolix in Oncology and Women’s Health

  • by

Shots: Myovant & Pfizer will jointly develop & commercialize ORGOVYX (relugolix) in advanced prostate cancer & if approved, relugolix combination tablet in women’s health in the US & Canada. Myovant will receive ~$4.2B including $650M upfront, $200M in regulatory milestones for FDA approvals for relugolix… Read More »Myovant Signs Agreement with Pfizer to Develop and Commercialize Relugolix in Oncology and Women’s Health